Product Code: ETC9970894 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Mucormycosis Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Mucormycosis Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Mucormycosis Market - Industry Life Cycle |
3.4 United States (US) Mucormycosis Market - Porter's Five Forces |
3.5 United States (US) Mucormycosis Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 United States (US) Mucormycosis Market Revenues & Volume Share, By Fungi Type, 2021 & 2031F |
3.7 United States (US) Mucormycosis Market Revenues & Volume Share, By Administration, 2021 & 2031F |
3.8 United States (US) Mucormycosis Market Revenues & Volume Share, By End users, 2021 & 2031F |
4 United States (US) Mucormycosis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of diabetes in the United States, as mucormycosis often affects individuals with uncontrolled diabetes. |
4.2.2 Growing awareness about mucormycosis among healthcare professionals leading to early diagnosis and treatment. |
4.2.3 Technological advancements in diagnostic tools and treatment options for mucormycosis. |
4.3 Market Restraints |
4.3.1 Limited availability of effective antifungal medications specifically targeting mucormycosis. |
4.3.2 High cost of treatment for mucormycosis, leading to financial burden on patients and healthcare systems. |
4.3.3 Lack of standardized guidelines for the management of mucormycosis, leading to variability in treatment approaches. |
5 United States (US) Mucormycosis Market Trends |
6 United States (US) Mucormycosis Market, By Types |
6.1 United States (US) Mucormycosis Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Mucormycosis Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 United States (US) Mucormycosis Market Revenues & Volume, By Azoles, 2021- 2031F |
6.1.4 United States (US) Mucormycosis Market Revenues & Volume, By Echinocandins, 2021- 2031F |
6.1.5 United States (US) Mucormycosis Market Revenues & Volume, By Polyenes, 2021- 2031F |
6.1.6 United States (US) Mucormycosis Market Revenues & Volume, By Allylamines, 2021- 2031F |
6.1.7 United States (US) Mucormycosis Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United States (US) Mucormycosis Market, By Fungi Type |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Mucormycosis Market Revenues & Volume, By Dermatophytes, 2021- 2031F |
6.2.3 United States (US) Mucormycosis Market Revenues & Volume, By Yeasts, 2021- 2031F |
6.2.4 United States (US) Mucormycosis Market Revenues & Volume, By Molds, 2021- 2031F |
6.2.5 United States (US) Mucormycosis Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United States (US) Mucormycosis Market, By Administration |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Mucormycosis Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 United States (US) Mucormycosis Market Revenues & Volume, By Topical, 2021- 2031F |
6.3.4 United States (US) Mucormycosis Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Mucormycosis Market, By End users |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Mucormycosis Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United States (US) Mucormycosis Market Revenues & Volume, By Specialty, 2021- 2031F |
6.4.4 United States (US) Mucormycosis Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.5 United States (US) Mucormycosis Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Mucormycosis Market Import-Export Trade Statistics |
7.1 United States (US) Mucormycosis Market Export to Major Countries |
7.2 United States (US) Mucormycosis Market Imports from Major Countries |
8 United States (US) Mucormycosis Market Key Performance Indicators |
8.1 Average time from symptom onset to diagnosis of mucormycosis. |
8.2 Patient mortality rate within 30 days of mucormycosis diagnosis. |
8.3 Number of clinical trials investigating new treatments for mucormycosis. |
8.4 Rate of hospital readmissions for mucormycosis patients. |
9 United States (US) Mucormycosis Market - Opportunity Assessment |
9.1 United States (US) Mucormycosis Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 United States (US) Mucormycosis Market Opportunity Assessment, By Fungi Type, 2021 & 2031F |
9.3 United States (US) Mucormycosis Market Opportunity Assessment, By Administration, 2021 & 2031F |
9.4 United States (US) Mucormycosis Market Opportunity Assessment, By End users, 2021 & 2031F |
10 United States (US) Mucormycosis Market - Competitive Landscape |
10.1 United States (US) Mucormycosis Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Mucormycosis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |